伏立康唑防治血液系统恶性肿瘤并发侵袭性真菌感染的疗效分析

Clinical observation of voriconazole prevention and cure on invasive fungai infection in patients with hematological malignancy

目的观察伏立康唑防治血液系统恶性肿瘤并发侵袭性真菌感染（IFI）的疗效和安全性。方法76例血液系统恶性肿瘤患者按随机数字表法分为观察组（39例）和对照组（37例），分别给予伏立康唑静脉序贯口服给药和伏立康唑静脉给药，比较丽组患者IFI及不良反应发生情况。结果观察组与对照组IFI确诊率分别为17．9％（7／39）、18．9％（7，37），临床诊断率分别为23．1％（9／39）、27．0％（10／37），拟诊率分别为59．0％（23／39）、54．1％（20，37），两组比较差异无统计学意义（P〉0．05）。观察组与对照组视觉障碍发生率分别为12．8％（5／39）、21．6％（8／37），转氨酶升高发生率分别为12．8％（5，39）、43．2％（16／37），两组比较差异有统计学意义（P〈0．05）。结论伏立康唑防治血液系统恶性肿瘤并发IFI效果好，可降低不良反应发生率，值得临床推广。

Objective To study the therapeutic effect and safety of voriconazole prevention and cure on invasive fungal infection （IFI） in patients with hematological malignancy. Methods Seventy-six patients with hematological malignancy were divided into observation group （39 eases） and control group （37 eases） by random digits table. The control group was given voriconazole of intravenous drip. The observation group was given voriconazole of intravenous drip sequence oral administration. The rates of occur IFI and adverse effect were compared between the two groups. Results In observation group and control group,the confirmed diagnose rates were 17.9% （ 7/39 ） and 18.9% （ 7/37 ）, clinical diagnose rates were 23.1% （9/39） and 27.0% （ 10/37 ）, para-diagnose rates were 59.0% （ 23/39 ） and 54. 1% （20/37）, there was no significant difference between the two groups（P〉 0.05 ）. In observation group and control group,the paropsia rates were 12.8%（5/39） and 21.6%（8/37）,transaminase elevated rates were 12.8%（5/39） and 43.2%（16/37）,there were significant differences between the two groups（P 〈 0.05 ）. Conclusion The vorieonazole of intravenous drip sequence oral administration and intravenous drip has a nice effect to IFI, and intravenous drip sequence oral administration could reduce the adverse effect.